ABP 692 (ocrelizumab biosimilar) / Amgen - LARVOL DELTA

Comparison Between ABP 692 and Ocrevus (Ocrelizumab) (clinicaltrials.gov) - P3 | N=152 | Active, not recruiting | Sponsor: Amgen | Trial primary completion date: Jan 2027 ➔ Apr 2027

Trial primary completion date • CNS Disorders • Multiple Sclerosis

Comparison Between ABP 692 and Ocrevus® (Ocrelizumab) (clinicaltrials.gov) - P3 | N=152 | Active, not recruiting | Sponsor: Amgen | Recruiting ➔ Active, not recruiting | N=444 ➔ 152

Enrollment change • Enrollment closed • CNS Disorders • Multiple Sclerosis

20230309: A Randomized, Double-blind, Parallel-group Study to Compare Pharmacokinetics, Pharmacodynamics, Clinical Effects, and Safety between ABP 692 and Ocrevus (Ocrelizumab) in Subjects with Relapsing-remitting Multiple Sclerosis (clinicaltrialsregister.eu) - P2/3 | N=375 | Active, not recruiting | Sponsor: Amgen Inc. | Recruiting ➔ Active, not recruiting

Enrollment closed • CNS Disorders • Multiple Sclerosis

Comparison Between ABP 692 and Ocrevus® (Ocrelizumab) (clinicaltrials.gov) - P3 | N=444 | Recruiting | Sponsor: Amgen | Not yet recruiting ➔ Recruiting

Enrollment open • CNS Disorders • Multiple Sclerosis